Research programme: gene-silencing oligonucleotides - Idera Pharmaceuticals

Drug Profile

Research programme: gene-silencing oligonucleotides - Idera Pharmaceuticals

Alternative Names: 3GA platform - Idera; Gene-silencing oligonucleotides - Idera; GSO - Idera; Third generation antisense platform - Idera; TLR antagonists for B cell lymphomas - Idera Pharmaceuticals; TLR anti-sense oligonucleotides - Idera

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Idera Pharmaceuticals; Leiden University; National Cancer Institute (USA)
  • Class Anti-inflammatories; Antineoplastics; Antisense oligonucleotides; Oligonucleotides
  • Mechanism of Action Apolipoprotein B inhibitors; Carrier protein modulators; DUX4 protein modulators; Gene silencing; Immunomodulators; MicroRNA inhibitors; PCSK9 protein inhibitors; RNA interference; Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists; Toll-like receptor 9 antagonists; Toll-like receptor antagonists; Toll-like receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Facioscapulohumeral muscular dystrophy; Interstitial cystitis; Ischaemia; Lupus nephritis; Uveitis
  • No development reported Autoimmune disorders; B cell lymphoma; Hypercholesterolaemia; Inflammation; Psoriasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in B-cell lymphoma in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hypercholesterolaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top